1. Home
  2. NSTS vs EQ Comparison

NSTS vs EQ Comparison

Compare NSTS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NSTS Bancorp Inc.

NSTS

NSTS Bancorp Inc.

N/A

Current Price

$11.86

Market Cap

58.7M

Sector

Finance

ML Signal

N/A

EQ

Equillium Inc.

HOLD

Current Price

$1.10

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSTS
EQ
Founded
1921
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.7M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NSTS
EQ
Price
$11.86
$1.10
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
6.4K
495.8K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,762,000.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
57.78
N/A
52 Week Low
$10.72
$0.27
52 Week High
$13.32
$2.35

Technical Indicators

Market Signals
Indicator
NSTS
EQ
Relative Strength Index (RSI) 68.20 51.32
Support Level $11.70 $0.84
Resistance Level $11.89 $1.26
Average True Range (ATR) 0.14 0.13
MACD 0.04 0.04
Stochastic Oscillator 84.94 46.66

Price Performance

Historical Comparison
NSTS
EQ

About NSTS NSTS Bancorp Inc.

NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: